Alimera Sciences Inc ALIM:NASDAQ

Last Price$5.23Cboe Previous Close - Real-Time Last Sale as of 4:00PM ET 11/30/21
Cboe Real-Time Quotes
Today's Change0.00(0.00%)
Bid (Size)$5.02 (100)
Ask (Size)$5.44 (200)
Day Low / High$5.15 - 5.50
Volume2.2 K
 

View Biotechnology IndustryPeer Comparison as of 11/30/2021

 

Alimera Sciences Inc ( NASDAQ )

Price: $5.23
Change: 0.00 (0.00%)
Volume: 2.2 K
4:00PM ET 11/30/2021
 
 

Microbot Medical Inc ( NASDAQ )

Price: $5.15
Change: +0.02 (0.39%)
Volume: 72.2 K
4:00PM ET 11/30/2021
 
 

Zero Gravity Solutions Inc ( OTC )

Price: $0.90
Change: 0.00 (0.00%)
Volume: 20.00
12:25PM ET 8/18/2021
 
 

Cyclacel Pharmaceuticals Inc ( NASDAQ )

Price: $3.78
Change: +0.20 (5.59%)
Volume: 138.3 K
12:30PM ET 12/01/2021
 
 

Navidea Biopharmaceuticals Inc ( NYSE MKT LLC )

Price: $1.24
Change: +0.01 (0.81%)
Volume: 19.9 K
9:30AM ET 12/01/2021
 

Read more news Recent News

Insider Buy: Alimera Sciences
5:31PM ET 11/04/2021 MT Newswires

Richard S Eiswirth Jr, Director, President and CEO, on November 03, 2021, executed a purchase for 28,005 shares in Alimera Sciences (ALIM) for $124,745....

-- Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q3 Revenue $12.2M, vs. Street Est of $12.4M
7:33AM ET 10/28/2021 MT Newswires

...

--Alliance Global Partners Adjusts Alimera Sciences PT to $14.50 From $16.50, Maintains Buy Rating
10:54AM ET 8/17/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--HC Wainwright Adjusts Alimera Sciences PT to $12 From $16, Maintains Buy Rating
10:33AM ET 8/16/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionAlimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA. View company web site for more details
Address6120 Windward Parkway
Alpharetta, Georgia 30005
Phone+1.678.990.5740
Number of Employees124
Recent SEC Filing12/01/20218-K
President, Chief Executive Officer & DirectorRichard S. Eiswirth
COO & SVP-Commercial Operations EuropePhilip John Ashman
Chief Financial OfficerJ. Philip Jones
Secretary, Vice President & General CounselChristopher S. Visick

Company Highlights

Price Open$5.34
Previous Close$5.23
52 Week Range$3.94 - 12.25
Market Capitalization$36.3 M
Shares Outstanding6.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/23/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.52
Beta vs. S&P 500N/A
Revenue$47.0 M
Net Profit Margin-2.11%
Return on Equity39.63%

Analyst Ratings as of 08/16/2021

Buy
3
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset